Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 6Esophageal Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Head and Neck Neoplasms 5Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Lung Neoplasms 3Carcinoma, Squamous Cell 3Stomach Neoplasms 2Nasopharyngeal Carcinoma 2Mouth Neoplasms 2Glioblastoma 2Carcinoma 2Adenocarcinoma 2Tonsillar Neoplasms 1Thrombocytopenia 1Resectable Esophageal Cancer 1Pharyngeal Neoplasms 1Pain 1Oropharyngeal Neoplasms 1Neoplasms, Multiple Primary 1Neoplasms by Site 1Neoplasms 1Nasopharyngeal Neoplasms 1Melanoma 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Limited Stage Small Cell Lung Cancer 1Irritable Bowel Syndrome 1

Interventions

Radiation 1Paclitaxel 1Chemoradiotherapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Resectable Esophageal Cancer × Chemoradiotherapy × Clear all
NCT03490292 2024-07-26

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

University of Wisconsin, Madison

Phase 1/2 Completed
22 enrolled 17 charts
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡